After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
Karuna Therapeutics has a schizophrenia treatment, KarXT, that’s up for approval in the U.S. and would expand Bristol Myers’s portfolio in neuroscience.
A deal would leave the combined entity with some $500 million of estimated cash with which to conduct future acquisitions of companies that sell life-sciences tools to drugmakers and academics.